<![CDATA[Targeting HIF-2 Alpha as a Novel Therapeutic Strategy]]>
Trending
- 95 monarchE: Subgroup Analysis of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer by Nodal Status
- 96 Efficacy and Safety of Abemaciclib in Younger Patients With Early Breast Cancer in the monarchE Trial
- GPX8+ cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma
- Crochet group donates beanies to cancer patients
- Scientists warn popular vitamin D supplement may have a “previously unknown” downside
- An oncostatin M receptor and chloride intracellular channel 1 crosstalk drives key oncogenic pathways in glioblastoma
- Quizartinib Regimen Appears Effective in FLT3-ITD+ AML Trial
- Stress granules shape ferroptosis in cancer

![<![CDATA[Targeting HIF-2 Alpha as a Novel Therapeutic Strategy]]> Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing](https://news.shareyourcancerstories.com/wp-content/uploads/2026/03/How-Rapid-Therapeutic-Evolution-Has-Complicated-RCC-Sequencing-768x432.png)